Anixa Biosciences Inc (NASDAQ:ANIX) Stock Has Average Price Target of $10.00 According to Brokerages

by · The Cerbat Gem

Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) has earned an average rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of equities analysts have issued reports on ANIX shares. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 30th. HC Wainwright reduced their price target on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th.

View Our Latest Analysis on ANIX

Insider Activity

In other Anixa Biosciences news, Director Lewis Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction dated Thursday, September 10th. The shares were purchased at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the purchase, the director owned 996,967 shares of the company’s stock, valued at approximately $2,721,719.91. This represents a 1.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 44,188 shares of company stock worth $138,334 over the last 90 days. 26.40% of the stock is currently owned by insiders.

Institutional Trading of Anixa Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC purchased a new position in Anixa Biosciences during the 2nd quarter valued at $30,000. Corient Private Wealth LP raised its holdings in Anixa Biosciences by 87.0% in the 2nd quarter. Corient Private Wealth LP now owns 37,400 shares of the company’s stock worth $105,000 after purchasing an additional 17,400 shares in the last quarter. AXQ Capital LP purchased a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $41,000. Canada Pension Plan Investment Board purchased a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $38,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $2.78 on Friday. The firm has a market cap of $96.63 million, a PE ratio of -8.69 and a beta of 0.51. Anixa Biosciences has a fifty-two week low of $2.32 and a fifty-two week high of $5.46. The business has a 50 day moving average price of $3.25 and a 200-day moving average price of $2.97.

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). Research analysts predict that Anixa Biosciences will post -0.31 EPS for the current year.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.

Featured Articles